{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:01:20Z","timestamp":1773712880793,"version":"3.50.1"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.wneu.2022.12.108","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T17:41:00Z","timestamp":1673372460000},"page":"136-145.e30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Systematic Review of Treatment Options and Therapeutic Responses for Lesions of the Sella and Orbit: Evidence-Based Recommendations"],"prefix":"10.1016","volume":"173","author":[{"given":"Christopher","family":"Cutler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Azab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Lucke-Wold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Curran","family":"Henson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarbir S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah A.","family":"Alt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-7937","authenticated-orcid":false,"given":"Michael","family":"Karsy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2022.12.108_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s42000-018-0064-y","article-title":"Non-adenomatous sellar lesions: single-centre 10-year experience","volume":"17","author":"Sousa Santos","year":"2018","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.wneu.2022.12.108_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ecl.2007.10.003","article-title":"Rare sellar lesions","volume":"37","author":"Glezer","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.wneu.2022.12.108_bib3","first-page":"504","article-title":"[Lymphocytic hypophysitis and hypertrophic pachymeningitis: description of a possible case associated to IgG4 pathologies]","volume":"60","author":"Blanco-Canto","year":"2015","journal-title":"Rev Neurol"},{"issue":"6 Suppl","key":"10.1016\/j.wneu.2022.12.108_bib4","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.wneu.2014.07.017","article-title":"Endoscopic endonasal surgery for nonadenomatous sellar\/parasellar lesions","volume":"82","author":"Barkhoudarian","year":"2014","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clineuro.2006.11.001","article-title":"Imaging of sellar and parasellar lesions","volume":"109","author":"Rennert","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib6","first-page":"89","article-title":"[CT and anatomo-pathologic examination in the diagnosis of cavernous sinus lesions]","volume":"111","author":"Haba","year":"2007","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"Supplement","key":"10.1016\/j.wneu.2022.12.108_bib7","first-page":"S154","article-title":"Sellar pathologies mimicking pituitary tumors","volume":"68","author":"Karmarkar","year":"2020","journal-title":"Neurol India"},{"key":"10.1016\/j.wneu.2022.12.108_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/jcem.86.3.7265","article-title":"The spectrum and significance of primary hypophysitis","volume":"86","author":"Cheung","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_bib9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.beem.2009.05.009","article-title":"Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary","volume":"23","author":"Carpinteri","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_bib10","doi-asserted-by":"crossref","first-page":"e14158","DOI":"10.1111\/ijcp.14158","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey","volume":"75","author":"Uzunkopru","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.wneu.2022.12.108_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib12","doi-asserted-by":"crossref","first-page":"117204","DOI":"10.1016\/j.jns.2020.117204","article-title":"Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: experience from a national health institute in Mexico","volume":"419","author":"Casallas-Vanegas","year":"2020","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_bib13","doi-asserted-by":"crossref","first-page":"101933","DOI":"10.1016\/j.msard.2020.101933","article-title":"A\u00a0long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.wneu.2022.12.108_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_bib17","first-page":"917","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib19","first-page":"311","article-title":"Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study","volume":"7","author":"Ong","year":"2020","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.wneu.2022.12.108_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","article-title":"Clinical evaluation of rituximab treatment for neuromyelitis optica","volume":"30","author":"Fern\u00e1ndez-Meg\u00eda","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.wneu.2022.12.108_bib21","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.wneu.2022.12.108_bib22","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib23","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2022.12.108_bib24","doi-asserted-by":"crossref","first-page":"102683","DOI":"10.1016\/j.msard.2020.102683","article-title":"Impact of rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","volume":"48","author":"Correa-Diaz","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib25","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.wneu.2022.12.108_bib27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.wneu.2022.12.108_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.wneu.2022.12.108_bib29","first-page":"2003","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jfma.2021.11.002","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","volume":"121","author":"Liu","year":"2022","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.wneu.2022.12.108_bib31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_bib33","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11136-020-02707-y","article-title":"Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data","volume":"30","author":"Schwartz","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.wneu.2022.12.108_bib34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in Aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib35","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.12.108_bib37","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.12.108_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib39","first-page":"688","article-title":"Primary non-necrotizing granulomatous hypophysitis mimicking pituitary adenomas","volume":"24","author":"Yildirim","year":"2014","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/a-1113-7777","article-title":"Clinical characteristics, management, and treatment outcomes of primary hypophysitis: a monocentric cohort","volume":"52","author":"Oguz","year":"2020","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.wneu.2022.12.108_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.20945\/2359-3997000000102","article-title":"Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience","volume":"63","author":"Imga","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.wneu.2016.07.071","article-title":"Clinical interrogation for unveiling an isolated hypophysitis mimicking pituitary adenoma","volume":"99","author":"Lee","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1507\/endocrj.46.505","article-title":"Lymphocytic hypophysitis and infundibuloneurohypophysitis; clinical and pathological evaluations","volume":"46","author":"Kamel","year":"1999","journal-title":"Endocr J"},{"key":"10.1016\/j.wneu.2022.12.108_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/a-0919-4388","article-title":"Primary hypophysitis: experience of a single tertiary center","volume":"129","author":"Korkmaz","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.wneu.2022.12.108_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1631\/jzus.B0820355","article-title":"Granulomatous hypophysitis: two case reports and literature review","volume":"10","author":"Shi","year":"2009","journal-title":"J\u00a0Zhejiang Univ Sci B"},{"key":"10.1016\/j.wneu.2022.12.108_bib46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/02688690120057664","article-title":"Lymphocytic and granulocytic hypophysitis: a single centre experience","volume":"15","author":"Buxton","year":"2001","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4103\/0028-3886.227293","article-title":"Corticosteroids in the management of lymphocytic hypophysitis: case series","volume":"66","author":"Panigrahi","year":"2018","journal-title":"Neurol India"},{"key":"10.1016\/j.wneu.2022.12.108_bib48","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.wneu.2019.06.021","article-title":"Sellar xanthogranuloma: a quest based on nine cases assessed with an anterior pituitary provocation test","volume":"130","author":"Fujio","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib49","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1507\/endocrj.K08E-043","article-title":"Lymphocytic hypophysitis occurring simultaneously with a functioning pituitary adenoma","volume":"55","author":"Cuthbertson","year":"2008","journal-title":"Endocr J"},{"key":"10.1016\/j.wneu.2022.12.108_bib50","first-page":"591","article-title":"Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Report of two cases","volume":"99","author":"Selch","year":"2003","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-6-560","article-title":"Autoimmune hypophysitis presenting with intracranial multi-organ involvement: three case reports and review of the literature","volume":"6","author":"Kanoke","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.wneu.2022.12.108_bib52","first-page":"143","article-title":"Lymphocytic hypophysitis","volume":"69","author":"Cauley","year":"2005","journal-title":"Conn Med"},{"key":"10.1016\/j.wneu.2022.12.108_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/eje.1.02183","article-title":"Primary hypophysitis: clinical-pathological correlations","volume":"155","author":"Gutenberg","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_bib54","first-page":"6737018","article-title":"Clinical features of painful ophthalmoplegia with a high-intensity ring appearance around the optic nerve on MRI: a case series","volume":"2020","author":"Nosaki","year":"2020","journal-title":"Case Rep Neurol Med"},{"key":"10.1016\/j.wneu.2022.12.108_bib55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2214\/ajr.150.2.413","article-title":"Tolosa-Hunt syndrome revisited: not necessarily a diagnosis of exclusion","volume":"150","author":"Kwan","year":"1988","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.wneu.2022.12.108_bib56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1440-1673.2008.01988.x","article-title":"Tolosa-Hunt syndrome: MRI appearances","volume":"52","author":"Jain","year":"2008","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.wneu.2022.12.108_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/jnnp.53.3.231","article-title":"Abnormality in the cavernous sinus in three patients with Tolosa-Hunt syndrome: MRI and CT findings","volume":"53","author":"Goto","year":"1990","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_bib58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1526-4610.1999.3905321.x","article-title":"Neuroimaging diagnosis of Tolosa-Hunt syndrome: MRI contribution","volume":"39","author":"de Arcaya","year":"1999","journal-title":"Headache"},{"key":"10.1016\/j.wneu.2022.12.108_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0333102412475238","article-title":"A\u00a0comparison of benign and inflammatory manifestations of Tolosa-Hunt syndrome","volume":"33","author":"Hung","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.wneu.2022.12.108_bib60","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.1995.00540330053014","article-title":"Therapeutic considerations in patients with refractory neurosarcoidosis","volume":"52","author":"Agbogu","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcp042","article-title":"Presentations and outcomes of neurosarcoidosis: a study of 54 cases","volume":"102","author":"Pawate","year":"2009","journal-title":"QJM"},{"key":"10.1016\/j.wneu.2022.12.108_bib62","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.wneu.2022.12.108_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11102-015-0678-x","article-title":"Hypothalamic-pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review","volume":"19","author":"Anthony","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2022.12.108_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2014diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.wneu.2022.12.108_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/eje.0.1420365","article-title":"Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis","volume":"142","author":"Bullmann","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_bib66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archneur.60.3.426","article-title":"The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab","volume":"60","author":"Katz","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib67","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2004.04.026","article-title":"Inflammatory orbital pseudotumor with extension beyond the orbit","volume":"138","author":"Mahr","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_bib68","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/bjo.85.10.1220","article-title":"A\u00a0role for methotrexate in the managment of non-infectious orbital inflammatory disease","volume":"85","author":"Simth","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_bib69","first-page":"327","article-title":"Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation","volume":"31","author":"Eshraghi","year":"2019","journal-title":"J\u00a0Curr Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jocn.2020.08.001","article-title":"Clinical and pathological features of 124 patients with indistinguishable sellar lesions and central diabetes insipidus","volume":"80","author":"Wang","year":"2020","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2022.12.108_bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib72","doi-asserted-by":"crossref","first-page":"101488","DOI":"10.1016\/j.msard.2019.101488","article-title":"Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation","volume":"37","author":"Gmuca","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib73","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","article-title":"Neuromyelitis optica","volume":"10","author":"Wingerchuk","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib75","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib76","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib77","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib78","doi-asserted-by":"crossref","first-page":"e15944","DOI":"10.1097\/MD.0000000000015944","article-title":"A\u00a0pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder","volume":"98","author":"Mealy","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.wneu.2022.12.108_bib79","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.msard.2021.102849","article-title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","volume":"50","author":"Kim","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib80","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib81","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_bib82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006123-199704000-00010","article-title":"Lymphocytic and granulomatous hypophysitis: experience with nine cases","volume":"40","author":"Honegger","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2022.12.108_bib83","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/jnnp.67.3.398","article-title":"Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?","volume":"67","author":"Kristof","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_bib84","doi-asserted-by":"crossref","first-page":"bvaa048","DOI":"10.1210\/jendso\/bvaa048","article-title":"A\u00a0case series of patients with isolated IgG4-related hypophysitis treated with rituximab","volume":"4","author":"Boharoon","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"issue":"5 Pt 1","key":"10.1016\/j.wneu.2022.12.108_bib85","first-page":"681","article-title":"Giant-cell granulomatous hypophysitis: a distinct clinicopathological entity","volume":"71","author":"Scanarini","year":"1989","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_bib86","first-page":"18","article-title":"Rituximab treatment for isolated IgG4-related hypophysitis in a teenage female","volume":"2018","author":"Bullock","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.wneu.2022.12.108_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3928\/01913913-20190923-02","article-title":"Idiopathic orbital pseudotumor preceding systemic inflammatory disease in children","volume":"56","author":"Tsukikawa","year":"2019","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.wneu.2022.12.108_bib88","doi-asserted-by":"crossref","first-page":"e57126","DOI":"10.1371\/journal.pone.0057126","article-title":"Idiopathic orbital inflammation syndrome with retro-orbital involvement: a retrospective study of eight patients","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.wneu.2022.12.108_bib89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/eje.0.1420365","article-title":"Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis","volume":"142","author":"Bullmann","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis--diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.wneu.2022.12.108_bib91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000076534","article-title":"Neurosarcoidosis: clinical experience and diagnostic pitfalls","volume":"51","author":"Kellinghaus","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib92","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1445-5994.2011.02457.x","article-title":"Medically refractory neurosarcoidosis treated with infliximab","volume":"41","author":"Pereira","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.wneu.2022.12.108_bib93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.wnl.0000341278.26993.22","article-title":"Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil","volume":"72","author":"Moravan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_bib94","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1068-2506","article-title":"First clinical experience with anti-myelin oligodendrocyte glycoprotein antibody-positive optic neuritis","volume":"237","author":"Heckmann","year":"2020","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.wneu.2022.12.108_bib95","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0036-1583184","article-title":"Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination: clinical course, neuroimaging findings, and response to therapy","volume":"47","author":"Thulasirajah","year":"2016","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.wneu.2022.12.108_bib96","doi-asserted-by":"crossref","first-page":"577078","DOI":"10.1016\/j.jneuroim.2019.577078","article-title":"The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series","volume":"337","author":"Brayo","year":"2019","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.wneu.2022.12.108_bib97","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib98","first-page":"1280","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_bib99","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_bib100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0040-1722636","article-title":"Not a tumor\u2014nonspecific orbital inflammation","volume":"82","author":"Garrity","year":"2021","journal-title":"J\u00a0Neurol Surg B Skull Base"},{"key":"10.1016\/j.wneu.2022.12.108_bib101","first-page":"512","article-title":"The management of sclerosing nonspecific orbital inflammation","volume":"22","author":"Kennerdell","year":"1991","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.wneu.2022.12.108_bib102","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0161-6420(96)30663-5","article-title":"Are systemic corticosteroids useful in the management of orbital pseudotumors?","volume":"103","author":"Mombaerts","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.wneu.2022.12.108_biba1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0161-6420(91)32115-8","article-title":"Long-term efficacy of orbital decompression for compressive optic neuropathy of Graves' eye disease","volume":"98","author":"Carter","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.wneu.2022.12.108_biba2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00701-009-0192-x","article-title":"Visual recovery following optic nerve decompression for chronic compressive neuropathy","volume":"151","author":"Bulters","year":"2009","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.wneu.2022.12.108_biba3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jcms.2018.12.009","article-title":"Navigation-assisted, endonasal, endoscopic optic nerve decompression for the treatment of nontraumatic optic neuropathy","volume":"47","author":"Liu","year":"2019","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.wneu.2022.12.108_biba4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-014-3179-8","article-title":"Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases","volume":"35","author":"Bitik","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.wneu.2022.12.108_biba5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01809268","article-title":"Pituitary granuloma and chronic inflammation of hypophysis: clinical and immunohistochemical studies","volume":"121","author":"Higuchi","year":"1993","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.wneu.2022.12.108_biba6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1631\/jzus.B0820355","article-title":"Granulomatous hypophysitis: two case reports and literature review","volume":"10","author":"Shi","year":"2009","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.wneu.2022.12.108_biba7","first-page":"688","article-title":"Primary non-necrotizing granulomatous hypophysitis mimicking pituitary adenomas","volume":"24","author":"Yildirim","year":"2014","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3171\/jns.1989.71.5.0681","article-title":"Giant-cell granulomatous hypophysitis: a distinct clinicopathological entity","volume":"71","author":"Scanarini","year":"1989","journal-title":"J Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006123-199704000-00010","article-title":"Lymphocytic and granulomatous hypophysitis: experience with nine cases","volume":"40","author":"Honegger","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2022.12.108_biba10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1507\/endocrj.46.505","article-title":"Lymphocytic hypophysitis and infundibuloneurohypophysitis; clinical and pathological evaluations","volume":"46","author":"Kamel","year":"1999","journal-title":"Endocr J"},{"key":"10.1016\/j.wneu.2022.12.108_biba11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/02688690120057664","article-title":"Lymphocytic and granulocytic hypophysitis: a single centre experience","volume":"15","author":"Buxton","year":"2001","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba12","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/jcem.86.3.7265","article-title":"The spectrum and significance of primary hypophysitis","volume":"86","author":"Cheung","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_biba13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/eje.1.02183","article-title":"Primary hypophysitis: clinical-pathological correlations","volume":"155","author":"Gutenberg","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_biba14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/1756-0500-6-560","article-title":"Autoimmune hypophysitis presenting with intracranial multi-organ involvement: three case reports and review of the literature","volume":"6","author":"Kanoke","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.wneu.2022.12.108_biba15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-014-0622-5","article-title":"Hypophysitis: a single-center case series","volume":"18","author":"Imber","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2022.12.108_biba16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.wneu.2016.07.071","article-title":"Clinical Interrogation for Unveiling an Isolated Hypophysitis Mimicking Pituitary Adenoma","volume":"99","author":"Lee","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.20945\/2359-3997000000102","article-title":"Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience","volume":"63","author":"Imga","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_biba18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/a-1113-7777","article-title":"Clinical Characteristics, Management, and Treatment Outcomes of Primary Hypophysitis: A Monocentric Cohort","volume":"52","author":"Oguz","year":"2020","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.wneu.2022.12.108_biba19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/a-0919-4388","article-title":"Primary hypophysitis: Experience of a Single Tertiary Center","volume":"129","author":"Korkmaz","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.wneu.2022.12.108_biba20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00415-019-09328-7","article-title":"Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions","volume":"266","author":"Ayrignac","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba21","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/rheumatology\/kev203","article-title":"Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients","volume":"54","author":"Lin","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.wneu.2022.12.108_biba22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/bjophthalmol-2015-307164","article-title":"Intraorbital corticosteroid injection for the treatment of IgG4-related ophthalmic disease","volume":"100","author":"Andrew","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.autrev.2017.07.020","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome","volume":"16","author":"Danlos","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.wneu.2022.12.108_biba24","first-page":"626","article-title":"Clinical features of immunoglobulin G4-related disease with central nervous system involvement: an analysis of 15 cases","volume":"38","author":"Peng","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.wneu.2022.12.108_biba25","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.wneu.2020.04.050","article-title":"Visual Outcomes After Endoscopic Endonasal Resection of Orbital Lesions","volume":"139","author":"Yang","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba26","article-title":"Hypophyseal Involvement in Immunoglobulin G4-Related Disease: A Retrospective Study from a Single Tertiary Center","volume":"2018","author":"Liu","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_biba27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-017-0852-4","article-title":"A case series of atypical features of patients with biopsy-proven isolated IgG4-related hypophysitis and normal serum IgG4 levels","volume":"21","author":"Yuen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2022.12.108_biba28","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820924556","article-title":"Two cases of immunoglobulin G4 (IgG4)-related hypophysitis diagnosed without pituitary biopsy","volume":"11","author":"Ma","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.wneu.2022.12.108_biba29","doi-asserted-by":"crossref","first-page":"bvaa048","DOI":"10.1210\/jendso\/bvaa048","article-title":"A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab","volume":"4","author":"Boharoon","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.wneu.2022.12.108_biba30","first-page":"159","article-title":"Lymphocytic hypophysitis: occurrence in two men","volume":"34","author":"Lee","year":"1994","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2022.12.108_biba31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3171\/jns.2003.99.3.0591","article-title":"Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Report of two cases","volume":"99","author":"Selch","year":"2003","journal-title":"J Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba32","first-page":"143","article-title":"Lymphocytic hypophysitis","volume":"69","author":"Cauley","year":"2005","journal-title":"Conn Med"},{"key":"10.1016\/j.wneu.2022.12.108_biba33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1507\/endocrj.K10E-334","article-title":"Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases","volume":"58","author":"Yang","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.wneu.2022.12.108_biba34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/cen.13354","article-title":"Primary lymphocytic hypophysitis: Clinical characteristics and treatment of 50 cases in a single centre in China over 18 years","volume":"87","author":"Wang","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.wneu.2022.12.108_biba35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4103\/0028-3886.227293","article-title":"Corticosteroids in the management of lymphocytic hypophysitis: Case series","volume":"66","author":"Panigrahi","year":"2018","journal-title":"Neurol India"},{"key":"10.1016\/j.wneu.2022.12.108_biba36","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.wneu.2019.01.250","article-title":"Clinical Features, Magnetic Resonance Imaging, and Treatment Experience of 20 Patients with Lymphocytic Hypophysitis in a Single Center","volume":"127","author":"Zhu","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.wneu.2022.12.108_biba38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0036-1583184","article-title":"Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy","volume":"47","author":"Thulasirajah","year":"2016","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.wneu.2022.12.108_biba39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.06.003","article-title":"Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases","volume":"86","author":"Wang","year":"2018","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba40","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.13753","article-title":"Acute idiopathic optic neuritis: not always benign","volume":"25","author":"Deschamps","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2019.05.006","article-title":"The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports","volume":"33","author":"Bellinvia","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577078","article-title":"The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series","volume":"337","author":"Brayo","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.wneu.2022.12.108_biba43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.msard.2018.10.003","article-title":"Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations","volume":"27","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1068-2506","article-title":"First Clinical Experience with Anti-myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis","volume":"237","author":"Heckmann","year":"2020","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.wneu.2022.12.108_biba46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4103\/0028-3886.294831","article-title":"Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated CNS Demyelination: Clinical Spectrum and Comparison with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder","volume":"68","author":"Ojha","year":"2020","journal-title":"Neurol India"},{"key":"10.1016\/j.wneu.2022.12.108_biba48","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba49","article-title":"Myelin Oligodendrocyte Glycoprotein (MOG) Optic Neuritis: A Case Series","volume":"13","author":"Nurul-Ain","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.wneu.2022.12.108_biba50","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10072-020-04892-7","article-title":"Anti-MOG-associated demyelinating disorders: two sides of the same coin","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00041327-200112000-00013","article-title":"The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study)","volume":"21","author":"Galetta","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.1995.00540330053014","article-title":"Therapeutic considerations in patients with refractory neurosarcoidosis","volume":"52","author":"Agbogu","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2014diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.wneu.2022.12.108_biba54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/eje.0.1420365","article-title":"Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis","volume":"142","author":"Bullmann","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2022.12.108_biba55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archneur.60.3.426","article-title":"The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab","volume":"60","author":"Katz","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000076534","article-title":"Neurosarcoidosis: clinical experience and diagnostic pitfalls","volume":"51","author":"Kellinghaus","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcp042","article-title":"Presentations and outcomes of neurosarcoidosis: a study of 54 cases","volume":"102","author":"Pawate","year":"2009","journal-title":"QJM"},{"key":"10.1016\/j.wneu.2022.12.108_biba58","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2022.12.108_biba59","first-page":"275","article-title":"Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review","volume":"32","author":"Riancho-Zarrabeitia","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.wneu.2022.12.108_biba60","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.wneu.2022.12.108_biba61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11102-015-0678-x","article-title":"Hypothalamic-pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review","volume":"19","author":"Anthony","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2022.12.108_biba62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/neurolint13020013","article-title":"Overcoming the Elusiveness of Neurosarcoidosis: Learning from Five Complex Cases","volume":"13","author":"Feizi","year":"2021","journal-title":"Neurol Int"},{"key":"10.1016\/j.wneu.2022.12.108_biba63","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of 7 patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba65","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba66","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba67","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba68","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_biba69","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba70","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jocn.2010.02.023","article-title":"Anti-tuberculosis treatment for Devic's neuromyelitis optica","volume":"17","author":"Feng","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.wneu.2022.12.108_biba71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.msard.2018.07.036","article-title":"Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders","volume":"25","author":"Fragomeni","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba73","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba74","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba75","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","article-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_biba79","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba80","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba82","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.wneu.2022.12.108_biba83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.wneu.2022.12.108_biba84","first-page":"461","article-title":"Clinical evaluation of rituximab treatment for neuromyelitis optica","volume":"30","author":"Fernandez-Megia","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.wneu.2022.12.108_biba85","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba86","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report","volume":"86","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2022.12.108_biba88","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.wneu.2022.12.108_biba89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11481-015-9646-5","article-title":"Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)","volume":"11","author":"Rommer","year":"2016","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.wneu.2022.12.108_biba90","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2022.12.108_biba91","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.wneu.2022.12.108_biba92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/ajts.AJTS_111_16","article-title":"Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica","volume":"11","author":"Batra","year":"2017","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba94","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12883-017-0903-5","article-title":"Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders","volume":"17","author":"Li","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba95","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba96","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.wneu.2022.12.108_biba97","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_biba98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba99","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","article-title":"Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients","volume":"381","author":"Bouzar","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.wneu.2022.12.108_biba102","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba104","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba105","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2022.12.108_biba106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2019.06.013","article-title":"Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city","volume":"34","author":"Ashtari","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba107","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba108","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba109","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.wneu.2022.12.108_biba110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba111","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015944","article-title":"A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder","volume":"98","author":"Mealy","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.wneu.2022.12.108_biba112","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.wneu.2022.12.108_biba113","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba114","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.wneu.2022.12.108_biba115","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101488","article-title":"Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation","volume":"37","author":"Gmuca","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba116","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.wneu.2022.12.108_biba117","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117204","article-title":"Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in Mexico","volume":"419","author":"Casallas-Vanegas","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba121","first-page":"311","article-title":"Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study","volume":"7","author":"Ong","year":"2020","journal-title":"Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.wneu.2022.12.108_biba122","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101506","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jca.21754","article-title":"Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee","volume":"35","author":"Ipe","year":"2020","journal-title":"J Clin Apher"},{"key":"10.1016\/j.wneu.2022.12.108_biba124","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11136-020-02707-y","article-title":"Response-shift effects in neuromyelitis optica spectrum disorder: a secondary analysis of clinical trial data","volume":"30","author":"Schwartz","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.wneu.2022.12.108_biba125","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jfma.2021.11.002","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","volume":"121","author":"Liu","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.wneu.2022.12.108_biba126","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba127","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102849","article-title":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","volume":"50","author":"Kim","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba128","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14158","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey","volume":"75","author":"Uzunkopru","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.wneu.2022.12.108_biba129","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102683","article-title":"Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","volume":"48","author":"Correa-Diaz","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba130","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba131","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103022","article-title":"Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico","volume":"52","author":"Gomez-Figueroa","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba132","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s10072-020-04933-1","article-title":"Male patients with neuromyelitis optica spectrum disorders: different clinical characteristics and worse steroid treatment response","volume":"42","author":"Li","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba133","first-page":"512","article-title":"The management of sclerosing nonspecific orbital inflammation","volume":"22","author":"Kennerdell","year":"1991","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.wneu.2022.12.108_biba134","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2004.04.026","article-title":"Inflammatory orbital pseudotumor with extension beyond the orbit","volume":"138","author":"Mahr","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.joco.2019.03.004","article-title":"Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation","volume":"31","author":"Eshraghi","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba136","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0040-1722636","article-title":"Not a Tumor-Nonspecific Orbital Inflammation","volume":"82","author":"Garrity","year":"2021","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.wneu.2022.12.108_biba137","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0161-6420(96)30378-3","article-title":"Idiopathic granulomatous orbital inflammation","volume":"103","author":"Mombaerts","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.wneu.2022.12.108_biba138","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/bjo.85.10.1220","article-title":"A role for methotrexate in the management of non-infectious orbital inflammatory disease","volume":"85","author":"Smith","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba139","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archotol.1997.01900040061010","article-title":"Optic nerve decompression for compressive neuropathy secondary to neoplasia","volume":"123","author":"Li","year":"1997","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.wneu.2022.12.108_biba140","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/adc.2009.175422","article-title":"Childhood optic neuritis clinical features and outcome","volume":"96","author":"Absoud","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.wneu.2022.12.108_biba141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00415-016-8073-8","article-title":"Plasma exchange response in 34 patients with severe optic neuritis","volume":"263","author":"Deschamps","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba142","first-page":"3","article-title":"Intravenous Immunoglobulin Treatment for Recurrent Optic Neuritis","volume":"56","author":"Altunrende","year":"2019","journal-title":"Noro Psikiyatr Ars"},{"key":"10.1016\/j.wneu.2022.12.108_biba143","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.msard.2018.10.013","article-title":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome","volume":"27","author":"Etemadifar","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.wneu.2022.12.108_biba144","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/aian.AIAN_334_20","article-title":"Clinical Features, Gender Differences, Disease Course, and Outcome in Neuromyelitis Optica Spectrum Disorder","volume":"24","author":"Singh","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.wneu.2022.12.108_biba145","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/archopht.119.9.1299","article-title":"Optic perineuritis: clinical and radiographic features","volume":"119","author":"Purvin","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba146","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1752-1947-4-404","article-title":"High-dose steroid therapy for idiopathic optic perineuritis: a case series","volume":"4","author":"Tatsugawa","year":"2010","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.wneu.2022.12.108_biba147","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/WNO.0000000000000264","article-title":"Optic Perineuritis in Behcet Disease","volume":"35","author":"Lai","year":"2015","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.wneu.2022.12.108_biba148","first-page":"181","article-title":"Optic perineuritis: a retrospective case series","volume":"10","author":"Bergman","year":"2017","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.wneu.2022.12.108_biba149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis","volume":"44","author":"Lopez-Chiriboga","year":"2020","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.wneu.2022.12.108_biba150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120035","article-title":"Optic perineuritis: A Canadian case series and literature review","volume":"430","author":"Xie","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.wneu.2022.12.108_biba151","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/rheumatology\/ker432","article-title":"Inflammatory lesions of the orbit: a single paediatric rheumatology centre experience","volume":"51","author":"Boulter","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.wneu.2022.12.108_biba152","article-title":"Idiopathic orbital inflammation syndrome with retro-orbital involvement: a retrospective study of eight patients","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.wneu.2022.12.108_biba153","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2214\/ajr.150.2.413","article-title":"Tolosa-Hunt syndrome revisited: not necessarily a diagnosis of exclusion","volume":"150","author":"Kwan","year":"1988","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.wneu.2022.12.108_biba154","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/jnnp.53.3.231","article-title":"Abnormality in the cavernous sinus in three patients with Tolosa-Hunt syndrome: MRI and CT findings","volume":"53","author":"Goto","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2022.12.108_biba155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1526-4610.1999.3905321.x","article-title":"Neuroimaging diagnosis of Tolosa-Hunt syndrome: MRI contribution","volume":"39","author":"de Arcaya","year":"1999","journal-title":"Headache"},{"key":"10.1016\/j.wneu.2022.12.108_biba156","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1440-1673.2008.01988.x","article-title":"Tolosa-Hunt syndrome: MRI appearances","volume":"52","author":"Jain","year":"2008","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.wneu.2022.12.108_biba157","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0333102412475238","article-title":"A comparison of benign and inflammatory manifestations of Tolosa-Hunt syndrome","volume":"33","author":"Hung","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.wneu.2022.12.108_biba158","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3928\/01913913-20190923-02","article-title":"Idiopathic Orbital Pseudotumor Preceding Systemic Inflammatory Disease in Children","volume":"56","author":"Tsukikawa","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.wneu.2022.12.108_biba159","article-title":"Clinical Features of Painful Ophthalmoplegia with a High-Intensity Ring Appearance around the Optic Nerve on MRI: A Case Series","volume":"2020","author":"Nosaki","year":"2020","journal-title":"Case Rep Neurol Med"},{"key":"10.1016\/j.wneu.2022.12.108_biba160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00000478-199806000-00011","article-title":"Xanthomatous hypophysitis","volume":"22","author":"Folkerth","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.wneu.2022.12.108_biba161","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.wneu.2019.06.021","article-title":"Sellar Xanthogranuloma: A Quest Based on Nine Cases Assessed with an Anterior Pituitary Provocation Test","volume":"130","author":"Fujio","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.12.108_biba162","doi-asserted-by":"crossref","first-page":"bvaa048","DOI":"10.1210\/jendso\/bvaa048","article-title":"A case series of patients with isolated IgG4-related hypophysitis treated with rituximab","volume":"4","author":"Boharoon","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.wneu.2022.12.108_biba163","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1445-5994.2011.02457.x","article-title":"Medically refractory neurosarcoidosis treated with infliximab","volume":"41","author":"Pereira","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.wneu.2022.12.108_biba164","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0161-6420(96)30663-5","article-title":"Are systemic corticosteroids useful in the management of orbital pseudotumors?","volume":"103","author":"Mombaerts","year":"1996","journal-title":"Ophthalmology"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022018137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022018137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:31:49Z","timestamp":1726633909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875022018137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":266,"alternative-id":["S1878875022018137"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2022.12.108","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Treatment Options and Therapeutic Responses for Lesions of the Sella and Orbit: Evidence-Based Recommendations","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2022.12.108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}